U2Bio Co., Ltd.

KQ:221800 Korea Diagnostics & Research
Market Cap
$178.84 Million
₩261.86 Billion KRW
Market Cap Rank
#18961 Global
#731 in Korea
Share Price
₩23200.00
Change (1 day)
-0.64%
52-Week Range
₩2875.00 - ₩28200.00
All Time High
₩28200.00
Categories
Companies in Korea Diagnostics & Research
About

U2Bio Co., Ltd. provides healthcare services in South Korea. The company also offers specimen testing services; digital healthcare services related to testing and health examinations; and bio-technology platforms. The company was founded in 2009 and is headquartered in Seoul, South Korea.

U2Bio Co., Ltd. (221800) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of March 2025: 0.011x

Based on the latest financial reports, U2Bio Co., Ltd. (221800) has a cash flow conversion efficiency ratio of 0.011x as of March 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩373.61 Million) by net assets (₩34.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

U2Bio Co., Ltd. - Cash Flow Conversion Efficiency Trend (2022–2024)

This chart illustrates how U2Bio Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

U2Bio Co., Ltd. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of U2Bio Co., Ltd. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
JTL Industries Ltd
NSE:JTLIND
 		0.002x
Metropolitan Kentjana Tbk
JK:MKPI
 		0.034x
Asian Granito India Limited
NSE:ASIANTILES
 		0.011x
Banque Nationale de Belgique S.A.
LSE:0DT1
 		N/A
Dimeco Inc
OTCQX:DIMC
 		N/A
Charlton Aria Acquisition Corporation Units
NASDAQ:CHARU
 		0.000x
Semperit AG Holding
LSE:0G29
 		0.037x
Simplex Infrastructures Limited
NSE:SIMPLEXINF
 		0.222x

Annual Cash Flow Conversion Efficiency for U2Bio Co., Ltd. (2022–2024)

The table below shows the annual cash flow conversion efficiency of U2Bio Co., Ltd. from 2022 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩34.43 Billion ₩-1.73 Billion -0.050x +25.22%
2023-12-31 ₩37.99 Billion ₩-2.55 Billion -0.067x -109.32%
2022-12-31 ₩33.84 Billion ₩24.41 Billion 0.721x --